IRCT201404065181N13 IRCT 2014-06-02 vhice chancellor of Comparison of using of recombinant Fsh long time with or without hMG in IVf/ICSI cycles Comparison of using of recombinant Fsh long acting with or without hMG in IVf/ICSI cycles 2014-12-20 anticipated 200 Complete https://irct.ir/trial/5557 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 3 Female infertility associated with anovulation. Intervention 1: Control group: A dose of 150 mcg corrifolitropin alfa received on the third day of the menstrual cycle , Antagonist drug Orgalutran, 5 mg is given on the seventh day. Then, during the monitoring cycle of seven days, if needed, will receive only the daily recombinant FSH. Ovarian response is followed by vaginal ultrasound, when at least one follicle greater than 18 mm and there were at least three follicles larger than 14-15 mm, HCG Pregnyl) will be injected with a dose of 10,000 units. Intervention 2: Intervention group: A dose of 150 mcg corrifolitropin alfa is administrated on the third day of the menstrual cycle. Antagonist drug Orgalutran, 5 mg is given on the seventh day. Then on the seventh day after the cycle if needed, hMG will administrated. Ovarian response is followed by vaginal ultrasound, when at least one follicle greater than 18 mm and there were at least three follicles larger than 14-15 mm, HCG Pregnyl) will be injected with a dose of 10,000 units.